342 related articles for article (PubMed ID: 23169326)
1. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.
Clouse K; Pettifor A; Maskew M; Bassett J; Van Rie A; Gay C; Behets F; Sanne I; Fox MP
AIDS; 2013 Feb; 27(4):645-50. PubMed ID: 23169326
[TBL] [Abstract][Full Text] [Related]
2. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
[TBL] [Abstract][Full Text] [Related]
3. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.
Grimsrud A; Cornell M; Schomaker M; Fox MP; Orrell C; Prozesky H; Stinson K; Tanser F; Egger M; Myer L;
J Epidemiol Community Health; 2016 Jun; 70(6):549-55. PubMed ID: 26700300
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
[TBL] [Abstract][Full Text] [Related]
5. HIV treatment outcomes among people with initiation CD4 counts >500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study.
Dorward J; Sookrajh Y; Gate K; Khubone T; Mtshaka N; Mlisana K; Ngobese H; Yende-Zuma N; Garrett N
J Int AIDS Soc; 2020 Apr; 23(4):e25479. PubMed ID: 32319203
[TBL] [Abstract][Full Text] [Related]
6. Attrition when providing antiretroviral treatment at CD4 counts >500cells/μL at three government clinics included in the HPTN 071 (PopART) trial in South Africa.
Bock P; Fatti G; Ford N; Jennings K; Kruger J; Gunst C; Louis F; Grobbelaar N; Shanaube K; Floyd S; Grimwood A; Hayes R; Ayles H; Fidler S; Beyers N;
PLoS One; 2018; 13(4):e0195127. PubMed ID: 29672542
[TBL] [Abstract][Full Text] [Related]
7. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
8. Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study.
Katz IT; Kaplan R; Fitzmaurice G; Leone D; Bangsberg DR; Bekker LG; Orrell C
PLoS Med; 2017 Nov; 14(11):e1002434. PubMed ID: 29136014
[TBL] [Abstract][Full Text] [Related]
9. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
[TBL] [Abstract][Full Text] [Related]
10. The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting.
Brennan AT; Maskew M; Sanne I; Fox MP
Trop Med Int Health; 2013 May; 18(5):619-31. PubMed ID: 23419157
[TBL] [Abstract][Full Text] [Related]
11. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.
Onoya D; Sineke T; Brennan AT; Long L; Fox MP
AIDS; 2017 Jul; 31(11):1593-1602. PubMed ID: 28463877
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vitamin D
Sudfeld CR; Mugusi F; Aboud S; Nagu TJ; Wang M; Fawzi WW
Trials; 2017 Feb; 18(1):66. PubMed ID: 28183335
[TBL] [Abstract][Full Text] [Related]
13. Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study.
Deconinck L; Yazdanpanah Y; Gilson RJ; Melliez H; Viget N; Joly V; Sabin CA
HIV Med; 2015 Apr; 16(4):219-29. PubMed ID: 25522796
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
[TBL] [Abstract][Full Text] [Related]
15. Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011.
Allam RR; Murhekar MV; Bhatnagar T; Uthappa CK; Nalini C; Rewari BB; Mehendale SM
Trans R Soc Trop Med Hyg; 2015 May; 109(5):325-33. PubMed ID: 25778736
[TBL] [Abstract][Full Text] [Related]
16. Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.
Nash D; Wu Y; Elul B; Hoos D; El Sadr W;
AIDS; 2011 Jul; 25(12):1523-33. PubMed ID: 21750418
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.
Alvarez-Uria G; Naik PK; Pakam R; Midde M
Glob Health Action; 2013 Sep; 6():21682. PubMed ID: 24028937
[TBL] [Abstract][Full Text] [Related]
18. When to start antiretroviral therapy in resource-limited settings.
Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
[TBL] [Abstract][Full Text] [Related]
19. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
20. The social and clinical characteristics of patients on antiretroviral therapy who are 'lost to follow-up' in KwaZulu-Natal, South Africa: a prospective study.
Peltzer K; Ramlagan S; Khan MS; Gaede B
SAHARA J; 2011; 8(4):179-86. PubMed ID: 23236959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
